Improving cancer treatment with a new method for targeted radiation therapy
Radiotheranostic host:guest pretargeting with Pb-203 and Pb-212
This study is exploring a new way to make cancer treatments using special antibodies safer and more effective by better targeting cancer cells while protecting healthy tissues, so patients can have improved treatment experiences.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-11058408 on NIH RePORTER |
What this research studies
This research focuses on developing a novel pretargeting platform that enhances the safety and effectiveness of monoclonal antibody-based radiopharmaceuticals for cancer treatment. By using a combination of curcubit[7]uril 'hosts' and adamantane 'guests', the approach aims to improve the targeting of cancer cells while minimizing radiation exposure to healthy tissues. The study seeks to create a system that is nonimmunogenic and adaptable to various antibodies and radionuclides, potentially leading to better outcomes in precision nuclear medicine.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with specific types of cancer who are undergoing or considering targeted radionuclide therapy.
Not a fit: Patients who do not have cancer or those whose cancer is not amenable to targeted radionuclide therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer therapies that specifically target tumors while reducing harm to surrounding healthy tissues.
How similar studies have performed: While pretargeting strategies have shown some promise in previous studies, this specific approach utilizing curcubit[7]uril and adamantane is novel and has not been extensively tested.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Houghton, Jacob — State University New York Stony Brook
- Study coordinator: Houghton, Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.